Molina-Sáenz Mónica María, Villa-Arango Ana María, Cardona-Villa Ricardo
Universidad de Antioquia, IPS Universitaria, Servicio Alergología Clínica. Grupo de Alergología Clínica y Experimental. Medellín, Colombia.
Rev Alerg Mex. 2017 Jan-Mar;64(1):52-65. doi: 10.29262/ram.v64i1.233.
In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions.
To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts.
Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system.
79.7 % of patients had rhinitis, 54.9 % asthma, 34.5 % conjunctivitis and 16.4 % atopic dermatitis. Out of 12,546 tyrosine-adsorbed extract doses, 45 systemic reactions were recorded: 12 were grade 1 (30 %), 27 grade 2 (67.5 %) and 1 was grade 3 (2.5 %); the reaction rate was 0.35 per 100 administered injections, for an incidence rate of 5.8 %. No fatal reactions occurred.
The frequency of systemic reactions with subcutaneous immunotherapy with Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis tyrosine-adsorbed extracts was similar to that reported with other extracts.
尽管变应原特异性免疫疗法（SIT）有诸多益处，但由于对严重不良反应的担忧，其在一些国家的使用受到限制。
评估接受酪氨酸吸附的粉尘螨和腐食酪螨提取物皮下免疫疗法的特应性皮炎、过敏性哮喘、过敏性鼻炎和过敏性结膜炎患者的全身不良反应。
对2010 - 2015年期间的773例诊断为IgE介导疾病的患者进行回顾性研究，根据世界变态反应组织皮下免疫疗法诱发的全身反应分类系统描述变应原特异性免疫疗法的安全性。
79.7%的患者患有鼻炎，54.9%患有哮喘，34.5%患有结膜炎，16.4%患有特应性皮炎。在12546剂酪氨酸吸附提取物中，记录到45例全身反应：12例为1级（30%），27例为2级（67.5%），1例为3级（2.5%）；反应率为每100次注射0.35例，发生率为5.8%。未发生致命反应。
使用酪氨酸吸附的粉螨、屋尘螨和热带无爪螨提取物进行皮下免疫疗法的全身反应频率与其他提取物报道的相似。
